Building Better Therapeutics November 19, :10am

Similar documents
In vivo effect of anti-inflammatory compounds on HIV-1 gp120 -mediated brain inflammation

Challenges. Benefits. Control of viral load in plasma. Drug-drug interactions. Adverse effects/drug toxicities. Delay in HIV drug resistance

Nuclear Receptors Mediated Induction of P-glycoprotein by Antiretroviral Drugs in Human Brain Microvessel Endothelial Cells

Drug Transport in the Brain: Models of BBB and Brain Parenchyma

Professor Jonathan Weber

EXPLORING THE IMPACT OF SEX DISCREPANCIES IN HIV TREATMENT AND CURE

Human Immunodeficiency Virus

With over 20 drugs and several viable regimens, the mo6vated pa6ent with life- long access to therapy can control HIV indefinitely, elimina6ng the

Page 1. Outline. Outline. Building specialized knowledge: HIV. Biological interactions. Social aspects of the epidemic. Programmatic actions

Immunodeficiency. (2 of 2)

HIV 101: Fundamentals of HIV Infection

Can HIV be cured? (how about long term Drug free remission?)

Progress against the HIV Epidemic: is the end in sight?

The HIV Cure Agenda. CHIVA Oct Nigel Klein. Institute of Child Health and Great Ormond Street Hospital, London, UK

Chapter 13 Viruses, Viroids, and Prions. Biology 1009 Microbiology Johnson-Summer 2003

2/10/2015. Switching from old regimens. HIV treatment revision: As simple as old versus new? What is an old regimen? What is an old regimen?

The use of human immunodeficiency virus (HIV) protease inhibitors

CHAPTER - IV OBJECTIVES OF THE STUDY

A VACCINE FOR HIV BIOE 301 LECTURE 10 MITALI BANERJEE HAART

Drug Penetration to Sanctuary Sites Oral vs. IV Administration

HIV & AIDS: Overview

MID 36. Cell. HIV Life Cycle. HIV Diagnosis and Pathogenesis. HIV-1 Virion HIV Entry. Life Cycle of HIV HIV Entry. Scott M. Hammer, M.D.

SUPPLEMENTAL INFORMATIONS

T Memory Stem Cells: A Long-term Reservoir for HIV-1

Fayth K. Yoshimura, Ph.D. September 7, of 7 HIV - BASIC PROPERTIES

Kevin R. Robillard, Md. Tozammel Hoque, and Reina Bendayan. Introduction

Can we eradicate HIV?

The Global State of HIV/AIDS. Presented By: Siobhan K. Young, MPH PhD Candidate at UNC Chapel Hill

ARV Mode of Action. Mode of Action. Mode of Action NRTI. Immunopaedia.org.za

Acquired Immune Deficiency Syndrome (AIDS)

T-Pharmacytes for the Targeted Eradication of HIV Reservoirs

Decay characteristics of HIV-1- infected compartments during combination therapy

Clinical Development of ABX464, drug candidate for HIV Functional Cure. Chief Medical Officer ABIVAX

HIV-1 Subtypes: An Overview. Anna Maria Geretti Royal Free Hospital

, virus identified as the causative agent and ELISA test produced which showed the extent of the epidemic

HIV INFECTION: An Overview

The importance of pharmacogenetics in the treatment of epilepsy

Fertility Desires/Management of Serodiscordant HIV + Couples

Fig. 1: Schematic diagram of basic structure of HIV

Changes in CD4+ cells mirna expression following exposure to HIV 1 Claudio Casoli

BIT 120. Copy of Cancer/HIV Lecture

CHARACTERIZATION OF HIV-1 POPULATIONS IN INFECTED CELLS

Loss of CD96 Expression as a New Biomarker for T-cell Senescence in HIV-1 Infection

HIV Diagnosis and Pathogenesis. HIV-1 Virion

I declare that I have no financial conflicts of interest

Viruses in the Mammalian Male Genital Tract and Their Effects on the Reproductive System

Structure and Function of ABC Transporters in Health and Disease

ART for HIV Prevention:

Role of metabolism in Drug-Induced Liver Injury (DILI) Drug Metab Rev. 2007;39(1):

IAS 2015 Towards an HIV Cure symposium Vancouver Immune recognition following latency reversal

HIV Transmission HASPI Medical Biology Lab 20

Low-Level Viremia in HIV

Medical Virology Immunology. Dr. Sameer Naji, MB, BCh, PhD (UK) Head of Basic Medical Sciences Dept. Faculty of Medicine The Hashemite University

Pharmacology Considerations for HIV Prevention

Advances in HIV science and treatment. Report on the global AIDS epidemic,

Supplementary Materials for

Oncolytic Viruses as a Potential Approach to Eliminate the HIV Reservoir

A PROJECT ON HIV INTRODUCED BY. Abdul Wahab Ali Gabeen Mahmoud Kamal Singer

Engineered Immune-Mobilising Monoclonal T Cell Receptors for HIV Cure

MID 36. Cell. HIV Life Cycle. HIV Diagnosis and Pathogenesis. HIV-1 Virion HIV Entry. Life Cycle of HIV HIV Entry. Scott M. Hammer, M.D.

Doctoral Degree Program in Marine Biotechnology, College of Marine Sciences, Doctoral Degree Program in Marine Biotechnology, Academia Sinica, Taipei,

DIFFERENTIAL IMPACT OF HIV-1 PROTEASE INHIBITORS ON SUBSETS OF CD4+ T-LYMPHOCYTES

Diagnosis and Initial Management of HIV/AIDS: What the Primary Care Provider Should Know

Importance of Viral Suppression to Reduce HIV Transmission: Recent Evidence

Learning Objectives. New HIV Testing Algorithm from CDC. Overview of HIV infection and disease 3/15/2016

Use of in vitro cell assays and noninvasive imaging techniques to reduce animal experiments in drug development

Towards a block and lock strategy: LEDGINs hamper the establishment of a reactivation competent HIV reservoir.

Body & Soul. Research update, 25 October 2016

Role of anti-inflammatory compounds in human immunodeficiency virus-1 glycoprotein120- mediated brain inflammation

8/10/2017. HIV UPDATE 2017 David M Stein DO, FACOI

Continuing Education for Pharmacy Technicians

Role of P-glycoprotein in the distribution of the HIV-protease inhibitor, atazanavir, in the

Tel: ; Fax: ;

CHART ELEVEN (11) KENYAN FIGURES (KENYA DEMOGRAPHIC HEALTH SURVEY REVISED 2004)

Can HPV, cervical neoplasia or. HIV transmission?

GLOBAL INVESTMENT IN HIV CURE RESEARCH AND DEVELOPMENT IN 2017 AFTER YEARS OF RAPID GROWTH FUNDING INCREASES SLOW

Guanhan Li. Section of Infections of the Nervous System National Institutes of Health, Bethesda, MD

Case Study. Dr Sarah Sasson Immunopathology Registrar. HIV, Immunology and Infectious Diseases Department and SydPath, St Vincent's Hospital.

HIV Immunopathogenesis. Modeling the Immune System May 2, 2007

The current standard of treatment for HIV/AIDS is the highly active antiretroviral therapy (HAART). This therapy typically consists of a triple

Summary and concluding remarks

Tricks in HIV s bag to counter vaginal or rectal microbicides

WHY... 8/21/2013 LEARNING OUTCOMES PHARMACOKINETICS I. A Absorption. D Distribution DEFINITION ADME AND THERAPEUIC ACTION

ACQUIRED IMMUNODEFICIENCY SYNDROME AND ITS OCULAR COMPLICATIONS

Outline. Epidemiology of Pediatric HIV 10/3/2012. I have no financial relationships with any commercial entity to disclose

Induction and Clearance of Latent HIV Infection:

Supplementary Online Content

Additional Presentation Demonstrates Potential Mechanisms for Unprecedented HIV Reservoir Depletion by SB-728-T

SEXUAL TRANSMISSION. SEXUAL TRANSMISSION under ART: Biological Considerations

The Canadian HIV Cure Enterprise (CanCURE) Team

Combining Pharmacology and Mutational Dynamics to Understand and Combat Drug Resistance in HIV

Ch 18 Infectious Diseases Affecting Cardiovascular and Lymphatic Systems

BUGS and DRUGS Part 2 March 13, 2013 Marieke Kruidering- Hall

HIV/AIDS. Biology of HIV. Research Feature. Related Links. See Also


DNA Genotyping in HIV Infection

Program to control HIV/AIDS

CROI 2016 Review: Immunology and Vaccines

Outline. Aim with PMTCT. How are children transmitted. Prevention of mother-to-child transmission of HIV. How does HIV transmit to children?

Invited Review CROI 2018: Advances in Basic Science Understanding of HIV

Transcription:

Expression of ATP-binding Cassette (ABC) Membrane Drug Efflux Transporters in Human Testicular Tissue Billy Huang Supervisor: Dr. Reina Bendayan Department of Pharmaceutical Sciences Leslie Dan Faculty of Pharmacy Building Better Therapeutics November 19, 2013 11:10am

Outline Background Hypothesis Methods Results Summary Future Work

Background http://immunizebc.ca/sites/default/files/campaign/800px-hiv_epidem.png Accessed Aug 22, 1013 More than 30 million deaths 1 ~34 million people currently infected 1 1. UNAIDS. (2012). UNAIDS -Global Fact Sheet. World AIDS Day 2012 Global Fact Sheet. Retrieved August 09, 2013, from http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_factsheet_glob al_en.pdf

Background HAART Significant reduction of mortality thanks to HAART But still unable to eliminate latent infections in viral reservoirs Reservoirs defined as sites where viral replication persists with more stable kinetics than main pool of virus 1 CD4 T- Cells CNS MG T Blood 1. Dahl, V., Josefsson, L., & Palmer, S. (2010). HIV reservoirs, latency, and reactivation: prospects for eradication. Antiviral research, 85(1), 286 94. doi:10.1016/j.antiviral.2009.09.016

Background Testis believed to be latent reservoir SIV primarily infects lymphocytes in macaque testis 2 HIV receptors present in models of human testis 3 CXCR4, CCR5, CD4, DC-SIGN Variants in testis distinct from those in plasma 4 http://www.nature.com/clpt/journal/v83/n3/images/6100342f1.gifaccessedon Oct27, 2013 1. Le Tortorec, A., Le Grand, R., Denis, H., Satie, A.-P., Mannioui, K., Roques, P., Dejucq-Rainsford, N. (2008). Infection of semen-producing organs by SIV during the acute and chronic stages of the disease. PloS one, 3(3), e1792. doi:10.1371/journal.pone.0001792 2. Roulet, V., Satie, A.-P., Ruffault, A., Tortorec, A. Le, Denis, H., Guist hau, O., Dejucq-Rainsford, N. (2006). Susceptibility of Human Testis to Human Immunodeficiency Virus-1 Infection in Situ and in Vitro. The American Journal of Pathology, 169(6), 2094 2103. doi:10.2353/ajpath.2006.060191 3. Paranjpe, S., Craigo, J., Patterson, B., Ding, M., Barroso, P., Harrison, L., Gupta, P. (2002). Subcompartmentalization of HIV-1 quasispecies between seminal cells and seminal plasma indicates their origin in distinct genital tissues. AIDS research and human retroviruses, 18(17), 1271 80. doi:10.1089/088922202320886316

Background Low ARV permeability in testis possibly due to blood-testis barrier BTB made of Sertoli cells 1 Drug efflux transporters expressed at barrier regulate entry of xenobiotics 2,3 Drug uptake transporters and metabolic enzymes also affect permeability http://os1.amc.nl/celbiologie/20102011/auc/mannelijk/graphics/c0000001.jpg Accessed on Oct 25, 2013 1. Bronson, R. (2011). Biology of the male reproductive tract: its cellular and morphological considerations. American journal of reproductive immunology (New York, N.Y. : 1989), 65(3), 212 9. doi:10.1111/j.1600-0897.2010.00944.x 2. Su, L., Mruk, D. D., & Cheng, C. Y. (2011). Drug transporters, the blood-testis barrier, and spermatogenesis. The Journal of endocrinology, 208(3), 207 23. doi:10.1677/joe-10-0363 3. Robillard, K. R., Hoque, T., & Bendayan, R. (2012). Expression of ATP-binding cassette membrane transporters in rodent and human sertoli cells: relevance to the permeability of antiretroviral therapy at the blood-testis barrier. The Journal of pharmacology and experimental therapeutics, 340(1), 96 108. doi:10.1124/jpet.111.186916

Background 49 members in ABC superfamily discovered to date ATP-dependent transmembrane proteins Actively effluxes wide variety of drugs, drug conjugates and drug metabolites against concentration gradient B P-gp MRP BCRP Figure 1. Mouse P-gp crystal structure (Li, Jaimes and Aller, Protein Science. 2007)

Background Drug permeability in MGT usually reported as seminal plasma concentration 1 But semen is a complex mixture of secretions from several glands Need to evaluate contribution of each MGT component to semen 1. Else, L. J., Taylor, S., Back, D. J., & Khoo, S. H. (2011). Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antiviral therapy, 16(8), 1149 67. doi:10.3851/imp1919 Schematic of drug penetration between seminal plasma and blood plasma

Hypothesis Low ARV drug permeability in human testis is associated with the expression of drug transporters and drug metabolic enzymes

Methods Collaboration with Dr. Jean-Pierre Routyat the McGill University Health Centre and Dr. Pierre Brassard and Dr. Maud Belanger at the Metropolitan Centre of Plastic Surgery in Montreal Testicular tissue and blood samples currently being collected from uninfected and HIV-infected patients on HAART Assess mrna and protein expression of major drug transporters and drug metabolic enzymes using qpcr and western blot Quantify drug concentration in testis and blood Data from collaborator Nancy Sheehan at McGill Determine localization of drug transporters using immunofluorescence imaging

010 011 Results - qpcr 0.10 0.08 0.06 0.04 0.02 qpcr Data for Drug Efflux Transporters from Uninfected Individuals ABCB1 PBMC Testes 1.0 0.8 0.6 0.4 0.2 ABCC1 PBMC Testes 0.004 0.003 0.002 0.001 Expression Relative to GAPDH Expression Relative to GAPDH 0.00 0.0 009 008 009 010 011 008 009 010 011 008 0.4 0.3 0.2 0.1 ABCC4 PBMC Testes 0.000 Expression Relative to GAPDH 008 009 010 011 0.0 ABCC2 PBMC Testes Expression Relative to GAPDH 0.5 0.4 0.3 0.2 0.1 ABCG2 PBMC Testes Expression Relative to GAPDH 008 009 010 011 0.0

Results Western Blot Western Blots of ABC Efflux Transporters

Summary mrna expression of drug transporters varies in both testis and PBMCs between uninfected individuals ABCC4 and ABCG2 show higher expression in testis Previous studies on mrna expression profiles suggest both interindividual variation and variation between methods of quantification Protein expression of drug transporters detected in testicular tissue but absent in PBMCs Discrepancy between qpcr and western blot data in PBMCs could be result of post-transcriptional modifications Overall our initial data suggest a potential for drug transporter proteins to interact with antiretroviral drugs in human testis

Future Work Continue to collect testicular tissues from uninfected individuals and HIVinfected patients on HAART Examine drug transporter and drug metabolic enzyme localization using immunofluorescence Try to find and collect frozen testicular tissue, cell lysate or cdna from HIVinfected HAART-naïve patients Gather ARV concentration data

Acknowledgement s Dr. Md. TozammelHoque,OlenaKisand all the members of Dr. Reina Bendayan s lab Dr. Mohammed Ali Jenabian Chronic Viral Illness Service Dr. Jean-Pierre Routy McGill University Health Centre Dr. Pierre Brassard and Dr. Maud Belanger MetropolitanCentre of Plastic Surgery Nancy Sheehan Montreal Chest Institute CIHR Catalyst Grant (Dr. JP Routy, PI) Ontario Graduate Scholarship (B. H.) OHTN Career Scientist Award (Dr. R. Bendayan)